Roth MKM Reinstates Buy on Fortress Biotech, Announces $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has reinstated Fortress Biotech (NASDAQ:FBIO) with a Buy rating and set a price target of $10. This indicates a positive outlook on the company's stock.
March 15, 2024 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fortress Biotech has been reinstated with a Buy rating by Roth MKM analyst Jason Wittes, who also set a price target of $10, indicating a positive future outlook.
The reinstatement of a Buy rating and the setting of a $10 price target by a reputable analyst like Jason Wittes suggests a strong belief in the potential growth and value of Fortress Biotech. This is likely to generate positive investor sentiment and could lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100